KNSA compared with HRTX: revenue, margins and what each company keeps, and the suppliers and customers both name

KNSAKiniksa Pharmaceuticals International, plc

Mkt capRevenueRevenue

HRTXHeron Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

KNSAKiniksa Pharmaceuticals International, plc

HRTXHeron Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

KNSA2 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±13.9%▲+22.23%×1.60

Q2 FY26—▲+25.03%—

HRTX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±62.0%▼−31.74%×0.51

May 11 '26±32.7%▼−21.05%×0.65

= impliedKNSA realized, solidHRTX realized, hatchedOne scale, both sides: full bar = 63%× = |realized| ÷ impliedspan: KNSA 91d · HRTX 279dSource: market data

Q1 FY26

±34.8%

▲+11.11%

×0.32

Q3 FY25±24.3%▼−3.39%×0.14

KNSAKiniksa Pharmaceuticals International, plc

92.85▲+2.26%

Mkt cap$7.1BRevenue$286MQ3 FY26Revenue$678MFY25

HRTXHeron Therapeutics, Inc.

0.29▼−3.12%

Regular sessionNov 3 '26

Mkt cap$56.0MRevenue$38MQ2 FY26Revenue$155MFY25

Compare

Regular sessionNov 3 '26

KNSAKiniksa Pharmaceuticals International, plc

HRTXHeron Therapeutics, Inc.

92.85▲+2.26%

Price

0.29▼−3.12%

$7.1B

Mkt cap

$56.0M

Q3 FY26$286M

Revenue

$38MQ2 FY26

FY25$678M

Revenue

$155MFY25

KNSA92.85▲+2.26%vsHRTX0.29▼−3.12%Regular sessionNov 3 '26